Driven by the personal experience of the founder, FREmedica Technologies was launched in 2018 with the specific purpose of developing a frequency-based program to address Lyme disease: a disease undergoing rapid growth in North America and around the world.
Lyme is the most common vector-borne disease in the United States; presenting as many as 50 painful symptoms that cycle randomly. Lyme can cause joint pain, migraines, nerve damage, paralysis, eye issues, and insomnia among many other symptoms. It attacks every socioeconomic category. Current treatments for chronic Lyme disease are expensive, time consuming and invasive to little effect.
FREmedica is marketing the first wearable device designed to deliver a package of frequencies that help sufferers of Lyme disease. The WAVE 1 frequency emitter uses Targeted Pulsed Light Therapy to deliver frequencies specifically tailored to the symptoms caused by chronic Lyme disease.
WAVE 1 was created by a team of engineers led by founder Stephen Davis, and Stuart Gross, an advocate and practitioner of holistic health for over 20 years. Clients report relief from fatigue, brain fog, problems with mood, sleep, memory and concentration, sensitivity to sound and light, and a wide range of other symptoms.
Frequencies are a source of energy that carries information into the body and the cells that comprise it. The body then takes that information to restore proper cell function and support the immune system in dealing with health and wellness issues. The FREmedica frequency package specifically addresses Lyme disease.
FREmedica technology is completely different from other light technologies and, at the same time, complementary to other Lyme treatment modalities. The FREmedica Lyme Support Program is based on the body’s innate ability to heal itself. By restoring cell communication disrupted by illness, disease or emotional trauma, frequencies delivered by WAVE 1 empower the immune system and strengthen response to health and well-ness issues.
A PHASED BUSINESS MODEL
The initial focus is on people suffering from chronic Lyme disease in North America. They are targeted through health practitioners and Lyme support groups as well as through the FREmedica partners and affiliates program. Expansion into the global market will follow.
AN AGGRESSIVE SALES STRATEGY
The FREmedica approach to sales and marketing is multi-faceted and includes education and support, celebrity and medical practitioners, user testimonials and an extensive PR and digital advertising. FREmedica is supporting Lyme groups worldwide with information and product. The FREmedica website offers compelling and current updates on finding relief from Lyme disease.
WAVE 1 hardware will support a business model of subscription delivered frequencies which support the immune system in dealing with chronic Lyme disease. Following on 100 prototype WAVE 1 devices delivered in early 2018, with an additional 300 units being delivered in 2018, a soft launch led to sales of 1,070 devices. We are projecting sales of 2,000 devices for 2021.
A GROWING MARKET
It is estimated that nearly 4 million people in North America are living with Lyme disease and with little hope. Over 360,000 new cases are estimated every year. The difficulty of diagnosis leads to the belief that the actual case count may be as high as 40 million. Lyme disease is a worsening world-wide issue accelerated by climate change and rapid growth of the tick population.
An investment of $2.1 million will expand our FREmedica team, accelerate marketing, add inventory, continue R&D, and develop sales initiatives through 2021.
USE OF PROCEEDS
A UNIQUE OPPORTUNITY
Investors are invited to participate in an unprecedented, science-based and user-acclaimed approach to providing relief from Lyme disease. FREmedica stands at the threshold of filling a dominant role in defeating a disease that defies traditional treatment even as its presence expands throughout the world. FREmedica presents an opportunity to do well while doing good.